“Over the past year, the team has worked tirelessly to transform our business, and we are now seeing our progress taking hold and flowing through to our financial results.” (CEO)
“Where others may see risk, we see opportunity.” (CEO)
“Our highest priorities continue to be investing to accelerate organic growth and debt reduction to strengthen our financial position, followed by strategic acquisitions.” (CFO)
Prepared Metrics
Metric
Value
Speaker/Context
Total Revenue
$820.3M
Q3 2025 (CFO)
Organic Revenue Growth
5.1%
YoY (CEO, CFO)
Adjusted EBITDA
$170.1M
Q3 2025 (CEO, CFO)
Adjusted EBITDA Margin
20.7%
Q3 2025 (CEO, CFO)
Capital Expenditures
$94.2M
Q3 2025 (CFO)
Free Cash Flow
$66.8M
Q3 2025 (CFO)
Net Debt
$1.73B
Q3 2025 end (CFO)
Net Leverage Ratio
2.68x
Q3 2025 end (CEO, CFO)
Sleep Health New Starts
~130,000
Q3 2025 (CFO)
Q&A Batch (1-2 of 2)
Q1 — Eric Coldwell
Topic: 大型按人头付费协议过渡时间线及竞争对手动态
Key points:
Jason Clemens表示,公司依据合同签约日期交付,优先确保在人力和基础设施到位后才接收首批患者,对2026年预期持"适当保守"态度,预计增长上半年较慢、下半年加快。